

NOV 20 2002

U.S. PATENT & TRADEMARK OFFICE
L6C5

1 TTTCTCACTGACTATAAAAGAATAGAGAACCGCTTCAGTGACCGGCTGCCTGGCTGACTTACAGCAGTCAGACTCTGACAGGATC
91 ATGGCTATGATGGGGTCAGGGGGACCCAGCCTGGACAGACCTGGCTGATCGTATCAGTCAGTGCAGTCCTGACTCTGAGTCTCTGT
1 Met Ala Met Met Glu Val Gln Gly Gln Pro Ser Leu Gly Gln Thr Cys Val Leu Ile Val Leu Phe Thr Val Leu Ser Leu Cys
181 GTGGCTGTAACCTACCGTGTACTTACCAACCGAGCTGAACAGATGCCAGACAAGTACTCCAAAGTGGCATGCTGCTTAGAAAG
31 Val Ala Val Thr Tyr Val Tyr Phe Thr Asn Gln Glu Leu Ile Asp Lys Cys Ser Cys Ile Ala Cys Phe Leu Lys Glu
271 GATGACAGTTATTGGACCCCCAATGACCGAACAGAGCTATGAAACAGCCCCCTGCTGGCAAGTCAAGTGGCAACTCCGTCAAGCTCGTTAGAAAAG
61 Asp Asp Ser Try Trp Asp Pro Asp Glu Glu Ser Met Asn Ser Pro Cys Trp Gln Val Leu Ile Ser Pro Leu Val Arg Gly Pro Gln
361 ATGATTTGAGAACCTCTGAGCAACATTCTACAGTTCAAGAAAAGCAACAAAATATTTCCTCCCTAGTGCAGAGAAAGAGGTCCCTCAG
91 Met Ile Leu Arg Thr Ser Glu Ile Ser Thr Val Gln Glu Lys Gln Gln Asn Ile Ser Pro Leu Val Arg Glu Arg Gly Pro Gln
*
451 AGAGTACCGCTCACATAACTGGGACCAGGAAAGCAACACATTGCTCTCCAAACTCCCAAAGAATGAAAGGCTCTGGGCCCAA
121 Arg Val Ala His Ile Thr Gly Thr Arg Gly Arg Ser Asn Thr Leu Ser Ser Pro Asn Ser Pro Asn Ser Lys Asn Glu Lys Ala Leu Gly Arg Gly
541 ATAAACTCCTGGGAATCATCAAGGGAGTGGCATTCATTCCCTGAGCAACTTGCACCTTGAGGAATGGTCACTGGTCAATGAAAGGG
151 Ile Asn Ser Trp Glu Ser Ser Arg Ser Gly His Ser Phe Leu Ser Asn Leu His Glu Leu Ile His Glu Lys Gln Gly
631 TTTACTACATCTATTCCAACATACTTCGATTTCAGGAGGAATAAAAGAACACAAACAAACAAATGCTCCAATATATT
181 Phe Tyr Tyr Ile Tyr Ser Gln Thr Tyr Phe Arg Phe Gln Glu Glu Ile Lys Glu Asn Thr Lys Asn Asp Lys Cys Trp Ser Lys Asp Ala Glu Lys Gln Tyr Ile
721 TACAAATACACAAGTTATCTGACCCCTATATTGGTGTAGAAAGTGGCTAAAGATGGAGAAATGGACTTAT
211 Tyr Lys Tyr Thr Ser Tyr Pro Asp Pro Ile Leu Met Lys Ser Ala Arg Asn Ser Cys Trp Ser Lys Asp Ala Glu Lys Gln Met Val Gln Tyr Ile
811 TCCATCTATCAAGGGGAATATTGAGCTTAAGAAAATGACAGAAATTGGTCTCTGTAACAAATGAGCACTGATAGACATGGACCAT
241 Ser Ile Tyr Gln Gln Gly Ile Phe Glu Leu Ile Asp Arg Ile Phe Val Ser Val Thr Asn Glu His Leu Ile Asp Met Asp His
901 GAAGCCAGTTTCCGGCCTTTAGTTGGCTAACTGACCTGGAAAGAAAAAGCAATAACCTCAAAGTCACTATTCAAGTTTCAGGAT
271 Glu Ala Ser Phe Phe Gly Ala Phe Leu Val Gly Stp
991 GATACACTATGAACATGTTCAAAAAATCTGACCAAACAAACAGAAA

FIG. 1A

FIG. 1B

		B	C'	C'	B'	C'	C'	F	E	D	G	H	I
41BBL	80	DPAGLIDL RQGMF AQQVVAQ		NVLLIDCPFL		SIVYSDPGLACVSTJCG		GLSYKEDTKELWVA					
OX40L	52	VSH--RYPRIQSIVKVQFT	--	--EYKKEKG	--	F--ILTS--QKEDF	--	IMKYQVN--SVJIN					
CD27L	45	QQQLPLESLGWDVAFQLN	--	HTGFQQDPR	--	YRQGGPALGRSFTH	--	QPEFDKG--QIBRH					
CD30L	87	LCILKRAPFKKSMAVLLQVA	--	KHNKTRL	--	SWNKD--CILH	--	CIVYQDG--NLVJQ					
TNF	77	VRSSSRTPSDKPVAVVAN	--	PQAEGQI	--	QWLNRRAAN--AIIAN	--	CYEFDRDN--QLVWP					
Ltb	77	EEPETDLSPLGPAAHLIGA	--	PLKGQQL	--	QMETTEKEQ--AFLTS	--	GTQFSDA--EGIALP					
Lta	52	PKMHLAHSITLKPAAHLIGD	--	PSKQNSL	--	IPKANTDR--AFLQD	--	GPSTSSN--SLLVP					
MQ	113	MQ--KGDDQNPQIAAVISE	--	ASSKTTSVL	--	QWAEKGY--TMSNN-LVLLENG-	--	KOLDVK					
CD40L	113	PSPPPKEKKELRKVAAHLIGK	--	SNSRSML	--	EWEDTYGIV-VLIS--	--	CWYKXKG--GLVJN					
Apo1L	134	VRE--RGPQRVAAHLIGTGRSNTLSSPNSKNEKA	--	GRKINSW	--	NLHJPNNG--ELVJH							
Apo2L	114												
41BBL	137	KAGWYVYFQFELIRVVAGEGS	--	GSFSPALHILQPLRSAAAGAAAALATVVDLPPAS	--								
OX40L	97	CDGFYIISLKGTE-SQE	--	UNISLH-EQKDE--EP	--	LFQIKKKVRSVN	--						
CD27L	100	RDGYIYMVHIOYTLAICSSTTA SRH	--	HPTMIAVGICSPAS	--	-RSISLJRLS FH	--						
CD30L	135	FPGLYFPLQQLQFLYQCP	--	NNSTIDKIELLLINKHI	--	--KKQALIYTVCES	--						
TNF	128	SEGLWLYSQWVIFGGCP	--	STWVILHTTISRIA VSY	--	QTKVNLISAIKSPCQRETPE	--						
Ltb	129	QDGLYYYCIVGTRGRAPPGGDPQGRSVMVLRSSISYRAGGAY	--	PGTIPELLLEGAETVTVPVLDPARR	--								
Lta	103	TSGFYEYVY SQWVIECKAYSPKAT--SSPLYLAHEVQLFSSQY	--	PFHVPLJSQKMVYPGL	--								
CD40L	165	RQCLYYIYAOVNTFCNSNREA	--	SSQAPFIA SLCLKSPCR	--	--FERILIRAAANTHSSAK	--						
Apo1L	186	ETGLEYVY SKYNTFRGOSC	--	NNILPUSHKVIMRNNSK Y	--	PDOLVMEGKMMSYCT	--						
Apo2L	178	EKGFYIYT SQTYYFQEEIKENTK	--	NDKQMVQYIYKTSY	--	PDPDIIUMKSARNCSWSKDA	--						
41BBL	190	--SEARNSA FGFGQGRUHLS-A	--	CGRTQWHLTEARARHAWQLTGATVLC	--	CFRVTPPEIPAGLPSPRSE							
OX40L	137	--SLMVASLTYKD--	--	VITNMTTDNT-S	--	SDDEHVNNGGELILIHQNPGF		FCVL					
CD27L	149	--FHQGCCHYISORLTPFLAR	--	CDIJCINLTGTL-LPSRNTID	--	--ETEFFGVQWVRP							
CD30L	180	--GMQTKHYQVNLSQFLIDYLQVNNTI	--	SYNMDTFQYI-D	--	DSSTFPLEN--VLSIFLYSNSD							
TNF	184	GAEAKFWVEPITLGEGVEQLEK	--	CDRIJSAEINRPDMY	--	DAEESG--	--	QVYFGTLIA					
Ltb	195	QGYGPLWNTS VGFGLVQ LRR	--	CDIAYVNI SHPDMDY	--	DEARG--	--	KTF FCAVAVG					
Lta	160	--QEFMLHSWYHGA AFQI TQ	--	CDQJSTHTDGIPHIVLSPST	--	--VVFFGAFAL							
CD40L	217	--PCGQOSIHLGGMFELQP	--	CASVFVNVTDP SQVSHGCT	--	FTSFGLLK							
Apo1L	237	--GQMWARSSITDGA VFNLT S	--	ADHIVNVSEL-S	--	QTF FGLYK							
Apo2L	236	--EYGLY-SIVYCCGTEFEIKE	--	NDRIFTYSYTNE-H	--	EDMDHE--	--	ASFFGAFLVG					

FIG. 3A




FIG. 3B





FIG. 3C



11/20/02
j1042 U.S. PTO




FIG. 1C





FIG. 1D

FIG. 1E

11/20/02
j1042 S U.S. PTO

FIG. 4



j1042 U. S. PTO

11/20/02




FIG. 2E

11/20/02
jor42 u.s. pro

FIG. 2B




FIG. 2C





FIG. 2D




042 U. S. PTO
11/20/02

9D CELLS

CONTROL



APO-2L



ANTI-APO-1




FIG. 2A